| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Activated STAT3 correlates with prognosis of non-small cell lung cancer and indicates new anticancer strategies
|
Yu, Yang
|
|
2015
|
75 |
5 |
p. 917-922
|
artikel
|
| 2 |
A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies
|
Williamson, Stephen K.
|
|
2015
|
75 |
5 |
p. 1075-1087
|
artikel
|
| 3 |
A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3
|
Mau-Sørensen, Morten
|
|
2015
|
75 |
5 |
p. 1065-1073
|
artikel
|
| 4 |
Autophagy in cancer stem/progenitor cells
|
Lin, Yi-Hui
|
|
2014
|
75 |
5 |
p. 879-886
|
artikel
|
| 5 |
Dose selection of siltuximab for multicentric Castleman’s disease
|
Mayer, Christina L.
|
|
2015
|
75 |
5 |
p. 1037-1045
|
artikel
|
| 6 |
Effects of cyclosporine A on the hepatobiliary disposition and hepatic uptake of etoposide in an isolated perfused rat liver model
|
Khezrian, Mina
|
|
2015
|
75 |
5 |
p. 961-968
|
artikel
|
| 7 |
First-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy
|
Avisar, Noa
|
|
2015
|
75 |
5 |
p. 929-939
|
artikel
|
| 8 |
Ginkgolide B protects against cisplatin-induced ototoxicity: enhancement of Akt–Nrf2–HO-1 signaling and reduction of NADPH oxidase
|
Ma, Weijun
|
|
2015
|
75 |
5 |
p. 949-959
|
artikel
|
| 9 |
Levels of sirolimus in saliva and blood following oral topical sustained-release varnish delivery system application
|
Nudelman, Zakhar
|
|
2015
|
75 |
5 |
p. 969-974
|
artikel
|
| 10 |
Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia
|
Vang, Sophia Ingeborg
|
|
2015
|
75 |
5 |
p. 1089-1093
|
artikel
|
| 11 |
Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer
|
Tebbutt, Niall
|
|
2015
|
75 |
5 |
p. 993-1004
|
artikel
|
| 12 |
Organic cation transporter OCT6 mediates cisplatin uptake and resistance to cisplatin in lung cancer
|
Kunii, Eiji
|
|
2015
|
75 |
5 |
p. 985-991
|
artikel
|
| 13 |
Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy
|
Kraff, Stefanie
|
|
2015
|
75 |
5 |
p. 975-983
|
artikel
|
| 14 |
Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies
|
Mehren, Margaret von
|
|
2015
|
75 |
5 |
p. 1047-1055
|
artikel
|
| 15 |
Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model
|
Cole, Diane E.
|
|
2015
|
75 |
5 |
p. 923-928
|
artikel
|
| 16 |
Plasma pharmacokinetics of the indenoisoquinoline topoisomerase I inhibitor, NSC 743400, in rats and dogs
|
Muzzio, Miguel
|
|
2015
|
75 |
5 |
p. 1015-1023
|
artikel
|
| 17 |
Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment
|
Lee, Haeng Jung
|
|
2015
|
75 |
5 |
p. 1005-1013
|
artikel
|
| 18 |
Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study
|
Patel, Yogesh T.
|
|
2015
|
75 |
5 |
p. 897-906
|
artikel
|
| 19 |
Protective effects of C-type natriuretic peptide on cisplatin-induced nephrotoxicity in Mice
|
Kimura, Toru
|
|
2015
|
75 |
5 |
p. 1057-1063
|
artikel
|
| 20 |
Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience
|
Petrioli, Roberto
|
|
2015
|
75 |
5 |
p. 941-947
|
artikel
|
| 21 |
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia
|
Jong, Jan de
|
|
2015
|
75 |
5 |
p. 907-916
|
artikel
|
| 22 |
Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor
|
Papadopoulos, Kyriakos P.
|
|
2015
|
75 |
5 |
p. 887-895
|
artikel
|
| 23 |
Validation of a fast and low-cost alkaline lysis method for gDNA extraction in a pharmacogenetic context
|
Ramos-Díaz, Ruth
|
|
2015
|
75 |
5 |
p. 1095-1098
|
artikel
|
| 24 |
Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor
|
Park, Inkeun
|
|
2015
|
75 |
5 |
p. 1025-1035
|
artikel
|
Tijdschrift beschrijving